Recent advances in diagnosis and therapy of human papillomaviruses

Bibliography

• ZUR HAUSEN H: In: Human Pathogenic Papillomaviruses. Zur Hausen H (Ed.), Springer Verlag, Heidelberg, Germany (1994):131–156.
   Google Scholar
• KOSS L: The Papanicolaou test for cervical cancer detection: a triumph and a tragedy. j Am. Med. Assoc. (1989) 261:737–743.
   Web of Science ®Google Scholar
• BURK RD, HO GYF, BEARDSLEY L, LEMPA M, PETERS M, BIERMAN R: Sexual behavior and partner characteris-tics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect. Dis. (1996) 174:679–689.
   PubMed Web of Science ®Google Scholar
• EVANDER M, EDLUND K, GUSTAFSSON A et al: Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect. Dis. (1995) 171:1026–1030.
   PubMed Web of Science ®Google Scholar
• BAUER HM, TING Y, GREER CE et al: Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA (1991) 265:472–477.
   PubMed Web of Science ®Google Scholar
• CATES W: Estimates of incidence and prevalence of sexually transmitted diseases in the United States. Sex. Transm. Dis. (1999) 26:S2–S7.
   Web of Science ®Google Scholar
• HOWLEY PM: In: Fields Virology. Fields BN, Knipe DM, Howley PM (Eds.), Lippincott-Raven, Philadelphia, USA (1996):2 :2045–2076.
   Google Scholar
• TROFATTER KF: Diagnosis of human papillomavirus genital tract infection. Am. J Med. (1997) 102:21–27.
   PubMedGoogle Scholar
• GISSMANN L, WOLNIK L, IKENBERG H, KOLDOVSKY U, SCHNURCH HG, ZUR HAUSEN H: Human papilloma-virus Type 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc. Nat. Acad. Sci. USA (1983) 80:560–563.
   PubMed Web of Science ®Google Scholar
• STOLER MH, BROKER TR: In situ hybridization detection of human papillomavirus DNA and messenger RNA in genital condylomas and a cervical carcinoma. Hum. Pathol. (1986) 17:1250–1258.
   PubMed Web of Science ®Google Scholar
• JACOBS MV, SNIJDERS PJ, VOORHORST FJ et al.: Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. J Clin. Pathol. (1999) 52:498–503.
   PubMed Web of Science ®Google Scholar
• REID R, LORINCZ AT: Human papillomavirus tests. Baillieres Clin. Obstet. Gynaecol (1995) 9:65–103.
   PubMed Web of Science ®Google Scholar
• HARNISH DG, BELLAND LM, SCHEID EE, ROHAN TE: Evaluation of human papillomavirus-consensus primers for HPV detection by the polymerase chain reaction. Mot. Cell. Probes (1999) 13:9–21.
   PubMed Web of Science ®Google Scholar
• HO GYF, BIERMAN R, BEARDSLEY L, CHANG CJ, BURKRD: Natural history of cervicovaginal papillomavirus infection in young women. N Engl. J. Med. (1998) 338:423–428.
   PubMed Web of Science ®Google Scholar
• GILLISON ML, KOCH WM, CAPONE RB etal.: Evidence fora causal association between human papillomavirus and a subset of head and neck cancers. J. Natl. Cancer Inst. (2000) 92:709–720.
   Google Scholar
• SHAMANIN V, ZUR HAUSEN H, LAVERGNE D et al.: Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J. Natl. Cancer Inst. (1996) 88:802–811.
   PubMed Web of Science ®Google Scholar
• RIETHMULLER D, GAY C, BERTRAND X et al.: Genitalhuman papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction. Diagn. Mot. Pathol. (1999) 8:157–164.
   PubMed Web of Science ®Google Scholar
• SCHIFFMAN MH, KIVIAT NB, BURK RD et al.: Accuracyand interlaboratory reliability of human papilloma-virus DNA testing by hybrid capture. J. Clin. Mkrobiol (1995) 33:545–550.
   PubMed Web of Science ®Google Scholar
• MELLORS JW, RINALDO CR, GUPTA P, WHITE RM, TODDJA, KINGSLEY LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (1996) 272:1167–1170.
   PubMed Web of Science ®Google Scholar
• KAUFMAN RH, ADAM E: Is human papillomavirus testing of value in clinical practise? Am. J Obstet. Gynecol. (1999) 180:1049–1053.
   Google Scholar
• FRANCO EL, FERENCZY A: Assessing gains in diagnosticutility when human papillomavirus testing is used as an adjunct to papanicolaou smear in the triage of women with cervical cytologic abnormalities. Am. J Obstet. Gynecol. (1999) 181 :382–386.
   PubMed Web of Science ®Google Scholar
• SCHIFFMAN M, HERRERO R, HILDESHEIM A et al.: HPVDNA testing in cervical cancer screening-Results from women in a high-risk province of Costa Rica. J. Am. Med. Assoc. (2000) 283:87–93.
   PubMed Web of Science ®Google Scholar
• KREBS HB: In: Clinical Obstetrics and Gynecology PitkinRM, Scott JR (Eds.), JB Lippincott, Philadelphia, USA (1989):32 :200–213.
   Google Scholar
• BEUTNER KR, FERENCZY A: Therapeutic approaches togenital warts. Am. J Med. (1997) 102:28–37.
   PubMedGoogle Scholar
• KRAUS SJ, STONE KM: Management of genital infectioncaused by human papillomavirus. Rev. Infect. Dis. (1990) 12:S620–S632.
   PubMedGoogle Scholar
• DOUGHERTY TJ, GOMER CJ, WEISHAUPT KR: Energeticsand efficiency of photoinactivation of murine tumor cells containing hematoporphyrin. Cancer Res. (1976) 36:2330–2333.
   PubMed Web of Science ®Google Scholar
• ABRAMSON AL, WARNER M, BRANDSMA J: The clinicaltreatment of laryngeal papillomas with hematopor-phyrin therapy. Arch. Otolmyngol. Head Neck Surg. (1988) 114:795–800.
   PubMed Web of Science ®Google Scholar
• SHIKOWITZ MJ, ABRAMSON AL, FREEMAN K, STEINBERGBM, NOURI M: Efficacy of DHE photodynamic therapy for respiratory papillomatosis: immediate and long-term results. Laryngoscope (1998) 108:962–967.
   PubMed Web of Science ®Google Scholar
• WIERRANI F, KUBIN A, JINDRA R et al: 5-Arninolevulinic acid-mediated photodynamic therapy of intraepithe-lial neoplasia and human papillomavirus of the uterine cervix-a new experimental approach. Cancer Detect. Prey. (1999) 23:351–355.
   PubMedGoogle Scholar
• TROFATTER KF: Interferon treatment of anogenital human papillomavirus-related diseases. Dermatol. Clin. (1991) 9:343–352.
   PubMed Web of Science ®Google Scholar
• TYRING SK: Treatment of condyloma acuminatum with interferon. Seminars in Oncology (1988) 15:35–40.
   PubMed Web of Science ®Google Scholar
• LEVENTHAL BG, KASHIMA HK, MOUNTS P et al.: Long term response of recurrent respiratory papillomatosis to treatment with lymphoblastoid interferon alpha-N1. N Engl. J. Med. (1991) 325:613–617.
   PubMed Web of Science ®Google Scholar
• TYRING SK, ARANY I, STANLEY MA et al.: A randomized, controlled, molecular study of con dylomata acuminata clearance during treatment with imiquimod. j Infect. Dis. (1998) 178:551–555.
   PubMed Web of Science ®Google Scholar
• MILLER RL, GERSTER JF, OWENS ML, SLADE HB, TOMAIMA: Irniquimod applied topically: a novel immune response modifier and new class of drug. Int. J. Immunopharmacol. (1999) 21:1–14.
   PubMed Web of Science ®Google Scholar
• WEEKS CE, GIBSON SJ: Induction of interferon andother cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro. J Interferon Res. (1994) 14:81–85.
   PubMedGoogle Scholar
• EDWARDS L, FERENCZY A, ERON L et al.:Self-administered topical 5% imiquimod cream for external anogenital warts. Arch. Dermatol. (1998) 134:25–30.
   PubMed Web of Science ®Google Scholar
• FIFE KH: New treatments for genital warts less thanideal: Abstract and commentary. J. Am. Med. Assoc. (1998) 279:2003–2004.
   PubMedGoogle Scholar
• PRUSINER P, SUNDARALINGAM M: A new class of synthetic nucleoside analogs with broad-spectrum antiviral properties. Nature (1973) 244:116–118.
   PubMed Web of Science ®Google Scholar
• GILBERT BE, WILSON SZ, KNIGHT V et al.: Ribavirinsmall-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1 /84. Antimicrob. Agents Chemother. (1985) 27 :309–313.
   PubMed Web of Science ®Google Scholar
• GELFAND EW, MCCURDY D, RAO CP, MIDDLETON PJ:Ribavirin treatment of viral pneumonitis in severe combined immunodeficiency disease. Lancet (1983) 2:732–733.
   PubMed Web of Science ®Google Scholar
• HALL CB, MCBRIDE JT, WALSH EE et al.: Aerosolizedribavirin treatment of infants with respiratory syncytial viral infection. N. EngI J. Med. (1983) 3 08:1443–1447.
   Web of Science ®Google Scholar
• MCCORMICK JB, KING IJ, WEBB PA et al.: lassa fever:effective therapy with ribavirin. N Engl. J. Med. (1984) 314:20–26.
   Web of Science ®Google Scholar
• ANDERSEN DO, MURRAY BK, ROBINS RK, NORTH JA: In vitro antiviral activity of ribavirin against picornavi-ruses. Antiviral Chem. Chemother. (1992) 3:361–370.
   Web of Science ®Google Scholar
• MCHUTCHINSON JG, GORDON SC, SCHIFF ER et al.: Interferon alpha 2B alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl. J. Med. (1998) 339:1485–1492.
   PubMed Web of Science ®Google Scholar
• SIDWELL RW: In: Clinical Applications of Ribavirin. Smith RA, Knight V, Smith JAD (Eds.), Academic Press, New York, USA (1984):19–32.
   Google Scholar
• STREETER DG, WITKOWSKI JT, KHARE GP et al.: Mechanism of action of 1-B-D-ribofuranosy1-1,2,4-triazole-3-carox amide (virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. USA (1973) 70:1174–1178.
   PubMed Web of Science ®Google Scholar
• FRANCHETTI P, GRIFANTINI M: Nucleoside andnon-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents. CUIT. Med. Chem. (1999) 6:599–614.
   PubMed Web of Science ®Google Scholar
• GOSWAMI BB, BOREK E, SHARMA OK, FUJITAKI J, SMITHRA: The broad-spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem. Biophys. Res. Commun. (1979) 89:830–836.
   PubMed Web of Science ®Google Scholar
• WRAY SK, GILBERT BE, NOALL MW, KNIGHT V: Mode of action of ribavirin: effect of nucleotide pool alteration on influenza virus ribonucleoprotein synthesis. Antiviral Res. (1985) 5:29–37.
   PubMed Web of Science ®Google Scholar
• NING Q, BROWN D, PARODO J et al.: Ribavirin inhibits viral-induced macrophage production of tumor necrosis factor, interleukin-1, procoag-ulant activity of fg12 prothrombinase and preserves Th1 cytokine production but inhibits Th2 response. J. Immunol. (1998) 160:3487–3493.
   PubMed Web of Science ®Google Scholar
• HULGREN C, MILICH DR, WEILAND 0, SALLBERG M: Theantiviral compound ribavirin modulates the T helper (Th)1/Lh2 subset balance in hepatitis B and C virus-specific immune responses. J. Gen. Virol. (1998) 79 :2381–2391.
   PubMed Web of Science ®Google Scholar
• GILBERT BE, KNIGHT W: Biochemistry and clinicalapplications of ribavirin. Antimicrob. Agents Chemother. (1986) 30:201–205.
   PubMed Web of Science ®Google Scholar
• OSTROW RS, FORSLUND KM, MCGLENNEN RC et al.: Ribavirin mitigates wart growth in rabbits at early stages of infection with cottontail rabbit papilloma-virus. Antiviral Res. (1992) 17:99–113.
   PubMed Web of Science ®Google Scholar
• LOBE DC, KREIDER JW, PHELPS WC: Therapeutic evalua-tion of compounds in the Scid-RA papillomavirus model. Antiviral Res. (1998) 40:57–71.
   PubMed Web of Science ®Google Scholar
• MCGLENNEN RC, ADAMS GL, LEWIS CM, FARAS AJ, OSTROW RS: Pilot trial of ribavirin for the treatment of laryngeal papillomatosis. Head Neck (1993)15:504–513.
   PubMed Web of Science ®Google Scholar
• MORRISON GA, KOTECHA B, EVANS JN: Ribavirin treatment for juvenile respiratory papillomatosis. Laryngol Otol (1993) 107:423–426.
   PubMed Web of Science ®Google Scholar
• KREIDER JW, BALOGH K, OLSON RO MARTIN JC: Treatment of latent rabbit and human papillomavirus infections with 9-(2-phosphonylmethoxy) ethyl guanine (PMEG). Antiviral Res. (1990) 14:51–58.
   PubMed Web of Science ®Google Scholar
• SNOECK R, WELLENS W, DESLOOVERE C et al.: Treatmentof severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine]. J. Med. Virol. (1998) 54:219–225.
   PubMed Web of Science ®Google Scholar
• SNOECK R, NOEL JC, MULLER C, DE CLERCQ E, BOSSENSM: Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J Med. Vim]. (2000) 60:205–209.
   PubMed Web of Science ®Google Scholar
• PREISER W, KAPUR N, SNOECK R, GROVES RW, BRINK NS:No apparent effect of cidofovir in epidermodysplasia verruciformis. j Clin. Vim]. (2000) 16:55–57.
   PubMed Web of Science ®Google Scholar
• PETERSEN BL, BUCHWALD C, GERSTOFT J, BRETLAU P,LINDEBERG H: An aggressive and invasive growth of juvenile papillomas involving the total respiratory tract. J. Laryngol. Otol. (1998) 112:1101–1104.
   PubMed Web of Science ®Google Scholar
• MUNOZ-JIMENEZ F, LOUREDO-MENDEZ AM, TUREGANO-FUENTES F, DEL VALLE-HERNANDEZ E, LACRUZ-PELEA C: Squamous cell carcinomas of the anus and infection with human papillomavirus in patients with AIDS. Eur. j Surg. (1996) 162:251–253.
   PubMedGoogle Scholar
• HOCKE C, LEROY V, MORLAT P et al.: Cervical dysplasiaand human immunodeficiency virus infection in women: Prevalence and associated factors. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GESCA). Eur. J. Obstet. Gynecol Reprod. Biol. (1998) 81:69–76.
   PubMed Web of Science ®Google Scholar
• PALEFSKY JM: Human papillomavirus infection andanogential neoplasia in human immunodefiency virus-positive men and women. J. Nail Cancer Inst. Monogr. (1998) 23:15–20.
   PubMedGoogle Scholar
• RUDLINGER R, SMITH IW, BUNNEY MH, HUNTER JA: Human papillomavirus infections in a group of renal transplant recipients. Br. J. Dermatol. (1986) 115:681–692.
   PubMed Web of Science ®Google Scholar
• BENTON EC, MCLAREN K, BARR BB et al: Human papillomavirus infection and its relationship to skin cancer in a group of renal allograft recipients. Curr. Pro& Dermatol. (1989) 18:168–177.
   PubMedGoogle Scholar
• UEZATO H, HAGIWARA K, MARUNO M et al: Detection ofhuman papillomavirus Type 58 in a case of a perianal Bowen's disease coexistent with adulty T-cell leukemia. J. Dermatol. (1999) 26:168–173.
   PubMedGoogle Scholar
• BREITBURD F, COURSAGET P: Human papillomavirusvaccines. Semin. Cancer Biol. (1999) 9:431–445.
   PubMed Web of Science ®Google Scholar
• TINDLE RW: Irnmunomanipulation strategies for thecontrol of human papillomavirus associated cervical disease. Immunol. Res. (1997) 16:387–400.
   PubMed Web of Science ®Google Scholar
• SCHILLER JT: Papillomavirus-like particle vaccines forcervical cancer. Mol Med. Today (1999) 5:209–215.
   PubMedGoogle Scholar
• DUGGAN-KEEN MG, BROWN MD, STACY SN, STERN PL:Papillomavirus vaccines. Front. Biosci. (1998) 3:D1192–1208.
   PubMedGoogle Scholar
• ZHOU J, SUN XY, STENZEL DJ, FRAZIER IH: Expression ofvaccinia recombinant HPV 16 LI and 12 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology (1991) 185:251–257.
   PubMed Web of Science ®Google Scholar
• KIRNBAUER R, TAUB J, GREENSTONE H et al.: Efficientself-assembly of human papillomavirus type-16 LI and L1-L2 into virus-like particles. J. Vim/. (1993) 67:6929–6936.
   Web of Science ®Google Scholar
• KIRNBAUER R, BOOY F, CHENG N, LOWY DR, SCHILLERJT: Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA (1992) 89:12180–12184.
   PubMed Web of Science ®Google Scholar
• HAGENSEE ME, YAEGASHI N, GALLOWAY DA: Self-assembly of human papillomavirus Type 1 capsids by expression of the LI protein alone or by coexpression of the LI and 12 capsid proteins. J Vim]. (1993) 67:315–322.
   Web of Science ®Google Scholar
• HEINO P, DILLNER J, SCHVVARTZ S: Human papilloma-virus Type 16 capsid proteins produced from recombi-nant Semliki Forest virus assemble into virus-like particles. Virology (1995) 214:349–359.
   PubMed Web of Science ®Google Scholar
• HOFMANN KJ, NEEPER MP, MARKUS HZ, BROWN DR, MULLER M, JANSEN KU: Sequence conservation within the major capsid protein of human papillomavirus (HPV) Type 18 and formation of HPV-18 virus-like particles in Saccharomyces cerevisiae. J. Gen. Vim]. (1996) 77:465–468.
   PubMed Web of Science ®Google Scholar
• HUSBAND AJ: Novel development vaccines for thecontrol of mucosal infection. Exp. Opin. Invest. Drugs (1994) 3:895–906.
   Google Scholar
• HUSBAND AJ: Novel vaccination strategies for thecontrol of mucosal infection. Vaccine (1993) 11:107–112.
   PubMed Web of Science ®Google Scholar
• SHELDRAKE RF, HUSBAND AJ, WATSON DL, CRIPPS AW:Selective transport of serum-derived IgA into mucosal secretions. J Immunol. (1984) 132:363–368.
   PubMed Web of Science ®Google Scholar
• BREITBURD F, KIRNBAUER R, HUBBERT NL et al.:Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Vim/. (1996) 69:3959–3963.
   Web of Science ®Google Scholar
• SUZICH JA, GHIM S-J, PALMER-HILL FJ et al.: Systemicimmunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA (1995) 92:11553–11557.
   PubMed Web of Science ®Google Scholar
• LIU XS, ABDUL-JABBAR I, QI YM, FRAZIER IH, ZHOU J:Mucosal immunization with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. Virology (1998) 252:39–45.
   PubMed Web of Science ®Google Scholar
• HAN R, CLADEL NM, REED CA, PENG X, CHRISTENSEN ND: Protection of rabbits from viral challenge by gene gun-based intracutaneous vaccination with a combination of cottontail rabbit papillomavirus El, E2, E6 and E7 genes. J Vim]. (1999) 73:7039–7043.
   Web of Science ®Google Scholar
• MONTGOMERY DL, SHIVER JW, LEANDER KR et al: Heterologous and homologous protection against influenza A by DNA vaccination: Optimization of DNA vectors. DNA Cell Biol. (1993) 12:777–783.
   PubMed Web of Science ®Google Scholar
• DONNELLY JJ, MARTINEZ D, JANSEN KU, ELLIS RW, MONTGOMERY DL, LIU MA: Protection against papillo-mavirus with a polynucleotide vaccine. J Infect. Dis. (1996) 1 7 3:314–320.
   Google Scholar
• SUNDARAM P, TIGELAAR RE, BRANDSMA JL: Intracuta-neous vaccination of rabbits with the cottontail rabbit papillomavirus (CRPV) LI gene products against virus challenge. Vaccine (1997) 15:664–671.
   PubMed Web of Science ®Google Scholar
• SUNDARAM P, TIGELAAR RE, XIAO W, BRANDSMA JL: Intracutaneous vaccination of rabbits with the E6 gene of cottontail rabbit papillomavirus provides partial protection against challenge. Vaccine (1998) 16:613–623.
   PubMed Web of Science ®Google Scholar
• LANPHEAR BP, LINNEMANN CC, CANNON CG, DERONDE MM: Decline of clinical hepatitis B in workers at a general hospital: relation to increasing vaccine-induced immunity. Clin. Infect. Dis. (1993) 16:10–14.
   PubMed Web of Science ®Google Scholar
• WAINWRIGHT RB, BULKOW LR, PARKINSON AJ, ZANIS C, MCMAHON BJ: Protection provided by hepatitis B vaccine in a Yupik Eskimo population-results of a 10-year study. J. Infect. Dis. (1997) 175:674–677.
   PubMed Web of Science ®Google Scholar
• DING L, ZHANG M, WANG Y, ZHOU S, KONG W, SMEGO RA: A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese. Clin. Infect. Dis. (1993) 17:475–479.
   PubMed Web of Science ®Google Scholar
• TINDLE RW, FRAZIER IH: Immunology of anogenital human papillomavirus (HPV) infection. Aust. NZ J. Obstet. Gynaecol. (1990) 30:370–375.
   PubMed Web of Science ®Google Scholar
• RESSING ME, SETTE A, BRANDT RM et al.: Human CTL epitopes encoded by human papillomavirus Type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HIA-A201 -binding peptides. J. Immunol. (1995) 154:5934–5943.
   PubMed Web of Science ®Google Scholar
• BORYSIEWICZ LK, FIANDER A, NIMAKO M et al.: A recombinant vaccinia virus encoding human papillo-mavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet (1996) 347:1523–1527.
   PubMed Web of Science ®Google Scholar
• PHELPS WC, ALEXANDER KA: Antiviral therapy for human papillomaviruses: rationale and prospects. Ann. Intern. Med. (1995) 123:368–382.
   PubMed Web of Science ®Google Scholar
• FRATTINI MG, LIM HB, LAIMINS LA: In vitro synthesis of oncogenic human papillomavirus requires episomal genomes for differentiation-dependent late expres-sion. Proc. Natl. Acad. Sci. USA (1996) 93:3062–3067.
   PubMed Web of Science ®Google Scholar
• PHELPS WC, BARNES JA, LOBE DC: Molecular targets for human papillomaviruses: prospects for antiviral therapy. Antiviral Chem. Chemother. (1998) 9:359–377.
   PubMed Web of Science ®Google Scholar
• USTAV M, STENLUND A: Transient replication of BPV-1requires two viral polyp eptides encoded by the El and E2 open reading frames. EMBO J (1991) 10:449–457.
   PubMed Web of Science ®Google Scholar
• YANG L, MOHR I, FOUTS E, LIM DA, NOHAILE M, BOTCHAN MR: The El protein of bovine papilloma-virus 1 is an ATP-dependent DNA helicase. Proc. Natl. Acad. Sci. USA (1993) 90:5086–5090.
   PubMed Web of Science ®Google Scholar
• SEO Y-S, MULLER F, LUSKY M, HURWITZ J: Bovine papilloma virus (BPV)-encoded El protein contains multiple activities required for BPV DNA replication. Proc. Natl. Acad. Sci. USA (1993) 90:702–706.
   PubMed Web of Science ®Google Scholar
• BONNE-ANDREA C, SANTUCCI S, CLERTANT P, TILLIER F: Bovine papillomavirus El protein binds specifically DNApolymerase alpha but not replication protein A. J Virol. (1995) 69:2341–2350.
   PubMed Web of Science ®Google Scholar
• PARK P, COPELAND W, YANG L, WANG T, BOTCHAN M: The cellular DNApolymerase a primase is required for papillomavirus DNA replication and associates with the viral El helicase. Proc. Natl. Acad. Sci. USA (1994) 91:8700–8704.
   PubMed Web of Science ®Google Scholar
• SPECTOR FC, LIANG L, GIORDANO H, SIVARAJA M, PETERSON MG: Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex. J Virol. (1998) 72:6979–6987.
   PubMed Web of Science ®Google Scholar
• ALEXANDER KA, PHELPS WC: A fluorescence anisotropy study of DNA binding by HPV-11 E2C Protein: A hierarchy of E2-binding sites. Biochem. (1996) 35:9864–9872.
   PubMed Web of Science ®Google Scholar
• MONINI P, GROSSMAN SR, PEPINSKY B, ANDROPHY EJ, LAIMINS LA: Co-operative DNA binding of the E2 protein of bovine papillomavirus to adjacent E2-responsive sequences. J. Virol. (1991) 65:2124–2130.
   PubMed Web of Science ®Google Scholar
• LI R, KNIGHT J, BREAM G, STENLUND A, BOTCHAN M: Specific recognition nucleotides and their DNA context determine the affinity of E2 protein for 17 binding sites in the BPV-1 genome. Genes Develop. (1989) 3:510–526.
   PubMed Web of Science ®Google Scholar
• MCBRIDE AA, ROMANCZUK H, HOWLEY PM: The papillomavirus E2 regulatory proteins. J Biol. Chem. (1991) 266:18411–18414.
   PubMed Web of Science ®Google Scholar
• MOHR IJ, CLARK R, SUN S, ANDROPHY EJ, MACPHERSON P, BOTCHAN MR: Targeting the El replication protein to the papilllomavirus origin of replication by complex formation with the E2 transactivator. Science (1990) 250: 1694-1699.
   Google Scholar
• BLITZ I, LAIMINS LA: The 68 kilodalton El protein of bovine papillomavirus is a DNA binding phosphopro-tein which associates with the E2 transcriptional activator in vitro. J. Virol. (1991) 65:649–656.
   PubMed Web of Science ®Google Scholar
• SEDMAN J, STENLUND A: Co-operative interaction between the initiator El and transcriptional activator E2 is required for replication of bovine papillomavirus in vivo and in vitro. EMBO J (1995) 14:6218–6228.
   PubMed Web of Science ®Google Scholar
• DIXON EP, PAHEL GL, ROCQUE WJ et al.: The El helicase of human papillomavirus Type 11 binds to the origin of replication with low sequence specificity. Virology (2000) 270:345–357.
   PubMed Web of Science ®Google Scholar
• SKIADOPOULOS MH, MCBRIDE AA: Bovine papilloma-virus Type 1 genomes and the E2 transactivator protein are closely associated with mitotic chromatin. Virol. (1998) 72:2079–2088.
   Web of Science ®Google Scholar
• DAY PM, RODEN RBS, LOWY DR, SCHILLER JT: The papillomavirus minor capsid protein, 12, induces localization of the major capsid protein LI and the viral transcription/replication protein E2, to PML oncogenic domains. J Virol. (1998) 72:142–150.
   PubMed Web of Science ®Google Scholar
• HEGDE RS, GROSSMAN SR, LAIMINS LA, SIGLER PB: Crystal structure at 1.7 Ã of the bovine papillomavirus-1 E2 DNA-binding domain bound to its DNA target. Nature (1992) 359:505–512.
   Google Scholar
• HINES CS, MEGHOO C, SHETTY S, BIBURGER M, BRENOWITZ M, HEGDE RS: DNA structure and flexibility in the sequence-specific binding of papillo-mavirus E2 proteins. j Mol. Biol. (1998) 276:809–818.
   PubMed Web of Science ®Google Scholar
• ANTSON AA, BURNS JE, MOROZ OV et al.: Structure of the intact transactivation domain of the human papillomavirus E2 protein. Nature (2000) 403:805–809.
   PubMed Web of Science ®Google Scholar
• HARRIS SF, BOTCHAN MR: Crystal structure of the human papillomavirus Type 18 E2 activation domain. Science (1999) 284: 1673-1677.
   Google Scholar
• LIANG H, PETROS AM, MEADOWS RP et al: Solution structure of the DNA-binding domain of a human papillomavirus E2 protein: Evidence for flexible DNA -binding regions. Biochem. (1996) 35:2095–2103.
   PubMed Web of Science ®Google Scholar
• HAJDUK PJ, MEADOWS RP, FESIK SW: Discovering high-affinity ligands for proteins. Science (1997) 278:497–499.
   PubMed Web of Science ®Google Scholar
• HAJDUK PJ, DINGES J, MIKNIS GF et al.: NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein. J. Med. Chem. (1997) 40:3144–3150.
   PubMed Web of Science ®Google Scholar
• HUBER HE, KOBLAN KS, HEIMBROOK DC: Protein-protein interactions as therapeutic targets for cancer. Curr. Med. Chem. (1994) 1:13–34.
   Google Scholar
• BOGAN AA, THORN KS: Anatomy of hot spots in protein interfaces. j Mol. Biol. (1998) 280:1–9.
   PubMed Web of Science ®Google Scholar
• ZUR HAUSEN H: Papillomaviruses causing cancer: evasion from host-cell control in early events in car cin o gen e sis. J Natl. Cancer Inst. (2000) 92:690–698.
   PubMed Web of Science ®Google Scholar
• BAER H, ALLEN S, BRAUN L: Knowledge of human papillomavirus infection among young adult men and women: Implications for health education and research. J. Community Health (2000) 25:67–78.
   PubMed Web of Science ®Google Scholar
• THOMAS L: In: The Medusa and the Snail. Viking Press, New York, USA (1979):76–81.
   Google Scholar
• BURK RD: Pernicious papillomavirus infection. N Engl. J. Med. (1999) 341:1687–1688.
   PubMed Web of Science ®Google Scholar
• Scrip, April 27, 1999
   Google Scholar